Refer a Friend
Do you know someone with agitation associated with Alzheimer's dementia, or a carer who's loved one is showing signs of agitated behavior? They may be eligible to participate in the TRIAD Research Study.
What is the TRIAD Research Study?
The TRIAD Research Study is evaluating an investigational drug (also called the study drug) to determine if it might reduce the symptoms of agitation associated with Alzheimer’s dementia, as well as testing its safety and tolerability in participants. Participation in the TRIAD Research Study will include up to 9 office visits over a period of approximately 16 weeks. Throughout the study, the carer of the participant will complete a study diary daily, and will bring this diary with them to every study visit for review. The carer will also give the study drug to the participant twice a day: once in the morning, and once in the evening.
There are currently no treatments approved for patients diagnosed with agitation associated with Alzheimer’s dementia. By participating in the TRIAD Research Study, you could help to advance future treatment options for this condition.
Study Eligibility
TO PARTICIPATE IN THIS STUDY, PATIENTS MUST:
Be 50 to 90
years old
Have moderate to severe agitation associated with Alzheimer’s disease
Have a carer who can attend all study visits
Additional criteria for eligibility will apply. Study participants receive study-related medical exams and study drug at no cost. Reimbursement for time and travel may be available.
COMPLETE THE ELIGIBILITY QUESTIONNAIRE